|Bid||36.60 x 2900|
|Ask||37.10 x 1300|
|Day's Range||36.71 - 37.41|
|52 Week Range||24.10 - 46.62|
|Beta (5Y Monthly)||0.97|
|PE Ratio (TTM)||13.16|
|Earnings Date||Oct 28, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||46.38|
Boston Scientific's (BSX) Q3 sales are expected to have benefited from growing demand for less-deferrable procedures across most of the segments.
Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Align Technology's (ALGN) ClinCheck treatment-planning software's commercial availability is expected to boost doctor performances due to ready availability of treatment plans.